| Christopher Y Kim, MD | |
|
444 W Bourne Cir Ste 200, Farmington, UT 84025 | |
| (801) 776-0176 | |
| (801) 825-3904 |
| Full Name | Christopher Y Kim |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 20 Years |
| Location | 444 W Bourne Cir Ste 200, Farmington, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457650442 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0011X | Internal Medicine - Interventional Cardiology | 7608694-1205 (Utah) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 7908694-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davis Hospital And Medical Center | Layton, UT | Hospital |
| Lakeview Hospital | Bountiful, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Utah Podiatric Physicians And Surgeons Group Llc | 4183946940 | 10 |
| Utah Cardiology Pc | 6507763950 | 7 |
| Advanced Vein And Vascular Of Salt Lake City Llc | 8325460173 | 2 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Entity Name | Utah Cardiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477643179 PECOS PAC ID: 6507763950 Enrollment ID: O20031215000737 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Entity Name | Utah Podiatric Physicians And Surgeons Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174942460 PECOS PAC ID: 4183946940 Enrollment ID: O20141204002347 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Entity Name | Advanced Vein And Vascular Of Salt Lake City Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386272755 PECOS PAC ID: 8325460173 Enrollment ID: O20200624000454 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Entity Name | Advanced Vein And Vascular Of Southern Utah Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326679952 PECOS PAC ID: 9335563394 Enrollment ID: O20200723000473 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Entity Name | Advanced Vein And Vascular Of Utah Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093329427 PECOS PAC ID: 6406276765 Enrollment ID: O20201026003049 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Entity Name | Advanced Vein And Vascular Of Northern Utah, Llc |
|---|---|
| Entity Type | Part B Supplier - Independent Clinical Laboratory |
| Entity Identifiers | NPI Number: 1700490133 PECOS PAC ID: 0244640670 Enrollment ID: O20201113000427 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Entity Name | Advanced Vein And Vascular Of Northern Utah, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700490133 PECOS PAC ID: 0244640670 Enrollment ID: O20210326000629 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Y Kim, MD 444 W Bourne Cir Ste 200, Farmington, UT 84025-3657 Ph: (801) 397-3000 | Christopher Y Kim, MD 444 W Bourne Cir Ste 200, Farmington, UT 84025 Ph: (801) 776-0176 |
News Archive
Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Cegedim Relationship Management today announced that it has partnered with StratX to provide the most innovative, Life Sciences-specific training to its customer-facing employees.
› Verified 1 days ago
Bhavananda T Reddy, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir Ste 200, Farmington, UT 84025 Phone: 801-776-0174 Fax: 801-825-3904 | |
Stephanie L Olsen, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir Ste 200, Farmington, UT 84025 Phone: 801-776-0174 Fax: 801-825-3904 | |
Dr. Roja R Mulamalla, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir Ste 200, Farmington, UT 84025 Phone: 801-776-0174 Fax: 801-825-3904 | |
Chad B Mcbride, D.O Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir Ste 200, Farmington, UT 84025 Phone: 801-776-0174 Fax: 801-825-3904 | |
Daniel J Humiston, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir Ste 200, Farmington, UT 84025 Phone: 801-776-0174 Fax: 801-825-3904 | |
Sandeep Talwar, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir Ste 200, Farmington, UT 84025 Phone: 801-776-0174 Fax: 801-825-3904 |